GlassScriptPhysician profile
Sophia Lee
NPI 1588151401
$5,844.98
in general payments reported to CMS, 2019-2025
40 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $583 · 2023: $1,706 · 2024: $1,568 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,387 · Education: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,386.79 |
| Education | $760.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $585.70 | 2022-2025 | Jakafi, Monjuvi |
| Lilly USA, LLC | $473.70 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $456.31 | 2022-2025 | Ojjaara, Blenrep |
| Revance Therapeutics, INC. | $383.61 | 2025 | Daxxify |
| Seagen INC. | $347.87 | 2021-2023 | Tukysa |
| Jazz Pharmaceuticals INC. | $325.91 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $317.57 | 2022-2024 | Tavalisse, Rezlidhia |
| Gilead Sciences, INC. | $268.64 | 2023-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $244.04 | 2023-2024 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $227.25 | 2022-2025 | Onureg, Opdivo, Opdualag |
| Merz North America, INC. | $220.39 | 2023 | |
| Genzyme Corporation | $219.02 | 2025 | |
| Janssen Biotech, INC. | $212.24 | 2024-2025 | Tecvayli, Darzalex, Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $155.75 | 2024-2025 | Ninlaro |
| Stemline Therapeutics INC. | $148.53 | 2023-2024 | Orserdu |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $147.71 | 2023-2025 | Besremi |
| Pfizer INC. | $120.53 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $94.67 | 2024-2025 | Myrisk |
| Abbvie INC. | $91.90 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $88.20 | 2023-2025 | Calquence, Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $81.44 | 2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $78.05 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Astellas Pharma US INC | $69.99 | 2024 | |
| Celgene Corporation | $48.51 | 2025 | Reblozyl |
| Sobi, INC | $47.13 | 2025 | |
| Galderma Laboratories, L.P. | $38.80 | 2023 | |
| Blueprint Medicines Corporation | $34.42 | 2025 | Ayvakit |
| Regeneron Pharmaceuticals, INC. | $32.76 | 2023 | Libtayo |
| Beigene USA, INC. | $30.80 | 2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $30.73 | 2025 | |
| Tersera Therapeutics LLC | $29.10 | 2025 | Zoladex |
| Deciphera Pharmaceuticals INC. | $28.10 | 2024 | Qinlock |
| Geron Corporation | $26.87 | 2024 | Rytelo |
| Springworks Therapeutics, INC. | $23.79 | 2025 | Ogsiveo |
| Pharmacosmos Therapeutics INC. | $22.92 | 2025 | Monoferric |
| Beone Medicines USA, INC. | $22.76 | 2025 | Brukinsa |
| Genmab U.S., INC. | $20.30 | 2025 | Epkinly |
| Exelixis INC. | $19.00 | 2024 | Cabometyx |
| Recordati_rare_diseases_inc. | $15.57 | 2025 | Enjaymo |
| Puma Biotechnology, INC. | $14.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sophia Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.